The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of dostarlimab monotherapy as first-line treatment in programmed cell death-ligand 1–positive recurrent/metastatic head and neck squamous cell carcinoma: Results from a phase 2 trial.
 
Robert Haddad
Employment - Dana-Farber Cancer Institute
Leadership - NCCN
Stock and Other Ownership Interests - tosk
Consulting or Advisory Role - Abbvie; Abbvie; ALX Oncology; Astellas Pharma; AstraZeneca; aveo; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Eisai; EMD Serono; Genmab; Genzyme; GlaxoSmithKline; Johnson & Johnson/Janssen; Merck; PDS Biotechnology; RAPT Therapeutics; Scholar Rock
Research Funding - AstraZeneca (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kura Oncology (Inst); Merck (Inst); Merus (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Other Relationship - Boehringer Ingelheim; Hookipa Pharma; Incyte; ISA Pharmaceuticals; Nanobiotix
 
Makoto Tahara
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; Lilly; Merck Serono; MSD; Novartis; Ono Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Genmab; GlaxoSmithKline; Janssen; Lilly; Merck KGaA; MSD; Nanobiotix; Ono Pharmaceutical; Pfizer
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Nanobiotix (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
 
Paolo Bossi
Honoraria - BeiGene; Daiichi-Sankyo; Genmab/Seagen; GlaxoSmithKline; LEO Pharma; Merck; Merus; MSD Oncology; Nutricia; Pfizer; Regeneron; Sun Pharma
Consulting or Advisory Role - Daiichi-Sankyo; Genmab/Seagen; GlaxoSmithKline; Merck Serono; MSD Oncology; Nutricia; Sanofi/Regeneron; Sun Pharma
Research Funding - AstraZeneca (Inst); BeiGene (Inst); GlaxoSmithKline (Inst); Merck Serono (Inst); Merus NV (Inst); MSD Oncology (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Merck Serono
 
Nicholas Ramscar
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Hamza Khan
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Micki Hill
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Steven Pattishall
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Gary Carlson
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Arindam Dhar
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Lillian Siu
Leadership - Treadwell Therapeutics (I)
Consulting or Advisory Role - Aktis Oncology; Amgen; Arvinas; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Daiichi Sankyo/UCB Japan; EMD Serono; Gilead Sciences; GlaxoSmithKline; Incyte; LTZ Therapeutics; Marengo Therapeutics; Merck; Navire; Nerviano Medical Sciences; Pangea; Pangea; Roche; Systimmune; Systinn; Tubulis GmbH; Velivago; Voronoi Health Analytics
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); LegoChem Biosciences (Inst); Loxo/Lilly (Inst); Marengo Therapeutics (Inst); Medicenna (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Takara Bio (Inst)
Other Relationship - Canada's Drug Agency (CDA-AMC)